Author

M. Bellet

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Gris-Oliver· 1 shared A. Hurtado-Rodriguez· 1 shared A.-L. Borresen-Dale· 1 shared A.-M. Fosdahl· 1 shared E. Fiorito· 1 shared H. Bergholtz· 1 shared J. Arribas· 1 shared J. H. Norum· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Gris-Oliver

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Breast tumors escape endocrine therapy by ER-independent mechanisms triggered by the coordinated activities of HER2/HER3 and deacetylated FOXA1

S. Gilfillan, S. Wang, M. R. Katika, J. H. Norum, H. Bergholtz, E. Fiorito, S. Nordhagen, Y. Sharma, S. Singh, V. S. Somisety, A.-M. Fosdahl, S. Nord, O. Engebraaten, O. C. Lingjaerde, A.-L. Borresen-Dale, , A. Hurtado-Rodriguez

This study shows that HER2/HER3 signaling and FOXA1 deacetylation drive ER-independent growth in hormone-resistant breast tumors by altering FOXA1 chromatin binding and function.

bioRxiv · Sep 22, 2020 · PreprintCancer Biology

Personalized Cancer Therapy Prioritization Based on Driver Alteration Co-occurrence Patterns

L. Mateo, M. Duran-Frigola, A. Gris-Oliver, M. Palafox, M. Scaltriti, P. Razavi, S. Chandarlapaty, J. Arribas, M. Bellet, V. Serra, P. Aloy

The paper identifies actionable genomic vulnerabilities in cancer by analyzing driver alteration co-occurrence patterns and validates predictions in mice, improving drug response modeling from patient data.

bioRxiv · Sep 18, 2020Cancer Biology